Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 30340782.
- Also identified by DOI 10.1016/j.eururo.2018.09.048 and PMC identifier 6291437.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and that such genomic aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition and platinum, has increased interest in the utilisation of these drugs against a subset of these diseases. Here in we report three patients with advanced castration-resistant PCa with HRD defects having exceptional responses to carboplatin.
Medical subject headings
- Adenocarcinoma
- Antineoplastic Agents
- Carboplatin
- DNA Repair-Deficiency Disorders
- Prostatic Neoplasms, Castration-Resistant
- Recombinational DNA Repair